Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

Novo Nordisk (NVO) stock gains as the company launches a new Phase 3 trial for its next-gen weight loss drug CagriSema after ...

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

According to the article, that investor aims to influence the company's choice of a chief executive.

While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...